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Appropriate primary prevention of cardiovascular 
disease: does this mean more or less statin use?
Jane Smith, Associate professor, General Practice, Faculty of Health Science and 
Medicine, Centre for Research in Evidence-based Practice, Bond University, Gold Coast, 
Queensland 
Summary 
Treatment with HMG-CoA reductase inhibitors,  
commonly known as statins, is beneficial for  
people at high risk of a cardiovascular event.  
However, guidelines recommend against routine  
statin treatment for those with a lower risk. They  
also recommend waiting until after 45 years of age 
to assess cardiovascular risk in healthy individuals.  
Aboriginal and Torres Strait islander people  
should be assessed from age 35 years. These  
recommendations are based on current evidence of 
who is more likely to benefit from statin treatment.
Key words: antilipidaemic drugs, cholesterol, HMG-CoA reductase 
inhibitors.
(Aust Prescr 2011;34:169–72)
introduction
Cardiovascular disease is a common problem causing 16% of 
the total disease burden, second to cancer. The mortality from 
cardiovascular disease has decreased by at least 80% in the last 
50 years, mostly before the introduction of statins (HMG-CoA 
reductase inhibitors). Although Australians are living longer, 
greater rates of physical inactivity, obesity and diabetes all 
threaten this trend.1 
The absolute risk of developing cardiovascular disease is 
predictable using risk calculation tools.2 Statins are known to 
reduce this risk in people with existing ischaemic cardiovascular 
disease, or those at high risk of developing it − defined as more 
than 15% risk of an event in five years. However it is less clear 
whether people with a lower cardiovascular risk, benefit from 
statins. 
Statin use
The number of patients diagnosed with high cholesterol has 
doubled between 2004 and 2009.3 The focus on single risk 
factors like cholesterol translates to 27% of adult general practice 
patients being managed for cholesterol4 − three-quarters of them 
are treated with statins. 
Patients and health providers alike tend to focus on cholesterol, 
perhaps because it is an easy target to test and treat. A possible 
consequence of this is that statins are the most prescribed 
of all drugs both in quantity and cost on the Pharmaceutical 
Benefits Scheme (PBS). There are three individual statins in 
the top 10 of all prescribed drugs – atorvastatin, simvastatin 
and rosuvastatin.5 Suggestions have been made about both 
under- and over-prescribing of statins in Australia. Women are 
far more likely to be treated with statins relative to their risk for 
cardiovascular disease than men, with the exception of men in 
the highest socioeconomic group. Rural people are less likely to 
be treated with a statin.6 
Cardiovascular risk
The term cardiovascular risk refers to the risk of ischaemic  
disease defined as acute coronary events, angina, stroke, transient 
ischaemic events, and peripheral vascular disease with or  
without fatal outcomes. There are multiple modifiable factors that 
influence the risk of developing cardiovascular disease (Box 1).  
Modifying these factors can improve morbidity and mortality and  
includes lifestyle factors such as increasing physical activity and  
cardiorespiratory fitness, and not smoking.7,8 If these interventions 
do not sufficiently reduce the risk of cardiovascular disease,  
pharmacological interventions may need to be considered. 
Generally people under 45 years are likely to have a low 
risk of cardiovascular disease, as age is one of the biggest 
determinants of risk, and multiple risk factors are not common 
in younger people. 
A family history of high cholesterol affects 5–20% of the 
population, depending on how one defines high cholesterol.  
Box 1 
Modifiable risk factors for cardiovascular disease 
Smoking 
High blood pressure 
Elevated cholesterol (total or low density lipoprotein)
Decreased high density lipoprotein cholesterol 
Diabetes
obesity (large waist measurement, high body mass index)
Lifestyle (minimal exercise, poor nutrition, high stress, 
excess alcohol)
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This is sometimes confused with familial hypercholesterolaemia  
(LDL >4.9 mmol/L usually with tendon xanthoma) which affects  
1 in 500 (0.2%) people.9 This is a high risk condition and results in 
coronary heart disease or stroke at a young age (under 60 years). 
Risk calculation
Calculating absolute risk using Framingham data adapted 
for Australia is well validated, based on multiple factors 
including cholesterol levels, but is underused.2 These tools 
tend to overestimate the risk in those of European descent but 
underestimate the risk in high risk groups such as Aboriginal 
and Torres Strait Islander, Pacific Islander or Indian people. 
Easy-to-use online tools for calculating cardiovascular risk are 
shown in Box 2. 
Table 1 shows who should have a cardiovascular risk 
calculation. Conversely, some patients' risk is high enough to 
not need any risk calculation. These are patients who have 
had a previous cardiovascular event. It also includes some 
patients with hypercholesterolaemia, diabetes, hypertension or 
moderate to severe chronic kidney disease (Box 3). 
recommendations for cholesterol testing
About 8% of adult patient encounters in general practice  
involve cholesterol testing but evidence suggests most of 
these tests do not result in any benefit to patients.3,10 The 
Royal Australian College of General Practitioners guidelines 
for preventive activities in general practice recommend testing 
adults over 45 years of age for their cholesterol levels every 
five years (or from 35 years if Aboriginal and Torres Strait 
Islander).11,12 Similar recommendations are given by the 
National Vascular Disease Prevention Alliance (Table 1).2 
evidence
Most of the evidence about the effect of statins in primary 
prevention is based on treatment of high-risk males aged 55–65 
years.13 There is little evidence about benefit in younger age 
groups. In those at high risk, statins lower ischaemic event rates 
and all-cause mortality, and are cost-effective. This has not been 
shown in lower-risk populations.14 
Table 1 
who needs risk calculation for cardiovascular disease? 2
Patient characteristics recommendation *
All adults 45–75 years of age B (strong)
Aboriginal and Torres Strait Islander 
people from 35 years of age
C (medium)
Diabetes <60 years C (medium)
overweight or obese D (weak)
* Based on the National Vascular Disease Prevention 
Alliance guidelines
National Health and Medical Research Council gradings: 
A Body of evidence can be trusted to guide practice
B Body of evidence can be trusted to guide practice in most 
situations 
C Body of evidence provides some support for 
recommendation but care should be taken in its 
application 
D Body of evidence is weak and recommendation must be 
applied with caution 
Box 2
online tools for calculating cardiovascular risk
www.heartfoundation.org.au/information-for-professionals/
Clinical-Information/Pages/absolute-risk.aspx [cited 2011  
Nov 7]
www.racgp.org.au/redbook/app3 [cited 2011 Nov 7]
National Vascular Disease Prevention Alliance: Australian 
absolute cardiovascular disease risk calculator. 2010.  
www.cvdcheck.org.au [cited 2011 Nov 7]
www.knowyournumbers.co.nz/heart-age-forecast.aspx  
[cited 2011 Nov 7]
other sources of the same risk calculators are in the Royal 
Australian College of General Practitioners primary care 
sidebar and some pathology laboratory reports
Box 3
People at high risk of a cardiovascular event (>15% in the 
next 5 years) who therefore do not require cardiovascular 
risk calculation 2
Characteristics
Known cardiovascular disease
Diabetes with microalbuminuria 
(>20 microgram/minute or  
urinary albumin:creatinine ratio >2.5 mg/mmol for males 
and >3.5 mg/mmol for females)
Diabetes >60 years 
Moderate or severe chronic kidney disease 
(eGFR <45 mL/minute/1.73 m2)
Familial hypercholesterolaemia 
Serum cholesterol >7.5 mmol/L 
Systolic blood pressure >180 mmHg or diastolic >110 mmHg
eGFR estimated glomerular filtration rate
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Systematic reviews of trials differ in their conclusions about the 
benefits of statins in patients who do not have a high risk. When 
patients with prior cardiovascular disease are excluded, there 
is no evidence of benefit from statin therapy on all-cause 
mortality.13 This suggests that caution should be used when 
recommending statins for primary prevention of cardiovascular 
disease in those at low risk (that is with a risk of cardiovascular 
disease less than 2% in one year) because of limited benefit and 
a potential for harm (Table 2).15,16 
In those with moderate to severe chronic kidney disease, 
statin treatment reduces cardiovascular events but not overall 
mortality.17 However, statin treatment of those with less severe 
chronic kidney disease appears to reduce cardiovascular events 
and overall mortality.18
PBS listing
The PBS general statement for using lipid-lowering drugs 
defines patients at risk who would be expected to benefit from 
statin therapy. The wording is intended to mirror the absolute 
cardiovascular disease risk calculation, but is an imperfect match.
Conclusion 
It is likely that we are over-prescribing statins to low-risk 
patients. A focus on single risk factors such as high cholesterol 
promotes statin treatment. This will not benefit patients 
unless they have a high risk of cardiovascular disease, and 
it could result in harm. It is appropriate to assess absolute 
cardiovascular risk in people aged over 45 years (or from  
35 years if Aboriginal and Torres Strait Islander) using tools that 
integrate multiple risk factors.
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Table 2 
Benefits and harms associated with statin treatment 
over five years in patients at high risk† of cardiovascular 
disease 16
event Men women
Number needed to treat
Cardiovascular disease 33 37
Number needed to harm 
Myopathy 91 259
Liver dysfunction 142 136
Acute renal failure 346 434
Cataract 52 33
† Patients had a 20% or more risk of cardiovascular event 
over 10 years
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Self-test questions
The following statements are either true or false  
(answers on page 195)
1. Statins do not reduce overall mortality in people with 
severe renal impairment. 
2. The National Vascular Disease Prevention Alliance 
recommends assessing the absolute cardiovascular 
risk in people over the age of 75.
18. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, 
Johnson DW, et al. HMG CoA reductase inhibitors (statins) 
for people with chronic kidney disease not requiring dialysis. 
Cochrane Database Syst Rev 2009;2:CD007784.
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Top 10 drugs
These tables show the top 10 subsidised drugs for the year July 2010 – June 2011. 
Table 1
Top 10 drugs by DDD/1000 pop/day *†
Constituent drug PBS/rPBS ‡
1. atorvastatin 82.87
2. irbesartan 33.02
3. rosuvastatin 32.37
4. perindopril 29.94
5. paracetamol 26.88
6. ramipril 26.16
7. candesartan 25.25
8. simvastatin 23.90
9. esomeprazole 21.32
10. amlodipine 19.92
DDDs in this table include use in combination products
Table 2
Top 10 drugs by prescription counts †
Drug PBS/rPBS ‡
1. atorvastatin 11 020 969
2. esomeprazole 6 099 877
3. rosuvastatin 5 975 902
4. paracetamol 4 840 331
5. simvastatin 4 245 616
6. perindopril 3 995 257
7. pantoprazole 3 549 374
8. metformin hydrochloride 3 383 078
9. irbesartan 3 098 162
10. atenolol 3 070 515
Table 3 
Top 10 drugs by cost to government †
Drug Cost to  
government (A$)
DDD/1000 pop/day * 
PBS/rPBS ‡
Prescriptions 
PBS/rPBS ‡
1. atorvastatin 637 426 978 82.87 11 020 969
2. rosuvastatin 334 168 383 32.37 5 975 902
3. ranibizumab 310 399 773 – ¶ 146 272
4. esomeprazole 184 167 326 21.32 6 099 877
5. clopidogrel 173 946 446 10.94 2 774 567
6. salmeterol and fluticasone 173 934 061 – § 3 065 047
7. adalimumab 173 892 033 0.33 97 834
8. olanzapine 161 933 986 2.99 950 386
9. simvastatin 139 642 087 23.90 4 245 616
10. etanercept 122 729 015 0.24 69 742
* The defined daily dose (DDD)/thousand population/day is a more useful measure of drug utilisation than prescription counts. It 
shows how many people, in every thousand Australians, are taking the standard dose of a drug every day.
† Based on date of supply. Does not include private prescriptions or prescriptions under PBS co-payment. 
‡ PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme
¶ The World Health organization has not allocated a DDD for this drug
§ This combination does not have a DDD allocated
Source: Drug Utilisation Sub-Committee (DUSC) Database, as at September 2011. © Commonwealth of Australia.
